Roche's anti-TIGIT drug suffers a phase III cancer setback

被引：0
作者：
Mullard, Asher
机构：
来源：
NATURE REVIEWS DRUG DISCOVERY | 2022年 / 21卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：327 / 327
页数：1
相关论文
共 50 条
  • [41] PHASE 1 STUDY OF SEA-TGT, A HUMAN, NONFUCOSYLATED ANTI-TIGIT MONOCLONAL ANTIBODY WITH ENHANCED IMMUNE-EFFECTOR FUNCTION, IN PATIENTS WITH ADVANCED MALIGNANCIES (SGNTGT-001, TRIAL IN PROGRESS)
    Davar, Diwakar
    Ribrag, Vincent
    Sarkozy, Clementine
    Garralda, Elena
    Oberoi, Honey Kumar
    Mehta, Amitkumar
    Curigliano, Giuseppe
    Belli, Carmen
    Zain, Jasmine
    Herrera, Alex
    Sanborn, Rachel
    Dumbrava, Ecaterina
    Forero-Torres, Andres
    Ansell, Stephen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A503 - A503
  • [42] Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II KEYVIBE-005 study
    Toullec, C.
    Seo, S.
    Robinson, A. G.
    Chou, H-H.
    Salman, P.
    Ghiringhelli, F.
    Ozyilkan, O.
    Rojas, C. I.
    Sendur, M. A. N.
    Le Tourneau, C.
    Yen, C. J.
    Aksoy, S.
    Ochsenreither, S.
    Ruiz, E. P. Yanez
    Rha, S. Y.
    Shapira-Frommer, R.
    Liu, Q.
    Du Plessis, M.
    Keenan, T.
    Hsu, C-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S617 - S618
  • [43] KeyVibe-003: Randomized, double-blind, phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC
    Cho, Byoung Chul
    Juergens, Rosalyn A.
    Cheng, Ying
    de Castro, Gilberto, Jr.
    Erman, Mustafa
    Bauman, Jessica R.
    Takahashi, Toshiaki
    Schwarzenberger, Paul
    Li, Chengxiang
    Pietanza, M. Catherine
    Yang, James Chih-Hsin
    CANCER RESEARCH, 2022, 82 (12)
  • [44] Current Development of Anti-Cancer Drug S-1
    Chhetri, Pratima
    Giri, Anil
    Shakya, Suraj
    Shakya, Sujana
    Sapkota, Binaya
    Pramod, K. C.
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2016, 10 (11) : XE1 - XE5
  • [45] Lessons from phase III clinical trials on anti-VEGF therapy for cancer
    Jain, RK
    Duda, DG
    Clark, JW
    Loeffler, JS
    NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (01): : 24 - 40
  • [46] Lessons from phase III clinical trials on anti-VEGF therapy for cancer
    Rakesh K Jain
    Dan G Duda
    Jeffrey W Clark
    Jay S Loeffler
    Nature Clinical Practice Oncology, 2006, 3 : 24 - 40
  • [47] AdvanTIG-204: A phase 2, multicenter, randomized, 3-arm, open-label study investigating the preliminary efficacy and safety of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) + concurrent chemoradiotherapy (cCRT) in patients with untreated limited-stage small cell lung cancer (SCLC)
    Gong, Youling
    Pang, Qingsong
    Yu, Rong
    Zhu, Zhengfei
    Huang, Jiangqiong
    Cheng, Yufeng
    Zhong, Diansheng
    Wu, Hongbo
    Yoo, Seung Soo
    Dobbs, Tracy
    Bao, Zinan
    Zuo, Yunxia
    Wei, Boxian
    Sun, Pu
    Lu, You
    CANCER RESEARCH, 2024, 84 (07)
  • [48] Cancer Cell's Achilles Heels: Considerations for Design of Anti-Cancer Drug Combinations
    Gahramanov, Valid
    Vizeacoumar, Frederick S.
    Morales, Alain Morejon
    Bonham, Keith
    Sakharkar, Meena K.
    Kumar, Santosh
    Vizeacoumar, Franco J.
    Freywald, Andrew
    Sherman, Michael Y.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (24)
  • [49] The role of glutathione-S-transferase in anti-cancer drug resistance
    Townsend, DM
    Tew, KD
    ONCOGENE, 2003, 22 (47) : 7369 - 7375
  • [50] The role of glutathione-S-transferase in anti-cancer drug resistance
    Danyelle M Townsend
    Kenneth D Tew
    Oncogene, 2003, 22 : 7369 - 7375
12345